http://www.biospace.comBioSpace RSS GeneratorTue, 09 Feb 2010 07:05:52 GMT20http://rss.biospace.com/images/BSPLogo.gifhttp://www.BioSpace.com/news.aspx?SectionId=1Copyright (C) 2009http://www.biospace.com/news_story.aspx?StoryID=170062&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170070&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170082&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170103&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170105&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170095&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170055&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170054&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170073&full=1<p></p><p>ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. announced today that the company has decided to discontinue negotiations in its pursuit of the previously announced collaboration with ROVI Pharmaceuticals (Madrid: ROVI) to develop Novavax's virus-like-particle (VLP)-based vaccines against influenza in the country of Spain. This decision is due to the companies' inability to...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170059&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170058&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170060&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170053&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170056&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170049&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170052&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170139&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170152&full=1<div id"releaseBody"><p>SAINT LAURENT, QUEBEC--(Marketwire - February 08, 2010) - IntelGenx Corp. (TSX VENTURE: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSXV:IGX">IGX</a>)(OTCBB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerIGXT">IGXT</a>) ("IntelGenx") today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration ("FDA") regarding the...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170126&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170112&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170149&full=1<div id"releaseBody"><p>LOS ANGELES, CA--(Marketwire - February 05, 2010) - <table class"releaseLink"><tr><td class"releaseLink"><b>Highlighted Links</b></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid584535&attachid1170521">Full Special Report</a></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid584535&attachid1170522">FDA...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170067&full=1SHELTON, Conn., Feb. 8 /PRNewswire/ -- Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170081&full=1<p>Full enrollment occurs five months ahead of schedule</p><p></p><p>TSX Exchange Symbol: RVX</p><p></p><p>CALGARY, Feb. 8 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170111&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170117&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170119&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170107&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170125&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170127&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170098&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170123&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170128&full=1Heidelberg, Germany; February 08 2010: Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful completion of the preclinical development of its lead product AFM 13 for the treatment of Hodgkin's lymphoma. Following promising preclinical data the company is now preparing the start of its first clinical study with AFM 13. </p><p>Preclinical pharmacology, pharmacokinetic...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170156&full=1Geneva, Switzerland, 8 February 2010 - Addex Pharmaceuticals (SIX:ADXN), the allosteric modulation company, announced today that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. </p><p>In the first model, ADX71943 reversed complete Freund adjuvant (CFA)-induced reductions in withdrawal thresholds in a dose-related manner, with a minimum...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170138&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170143&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170166&full=1Venlo, The Netherlands - 08. February 2010 --- QIAGEN today announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has shown that variation in the PI3K gene could be a key biomarker for use as a companion diagnostic with certain cancer treatments. The studies...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170167&full=1February 8, 2010 -- 3SBio Inc. in-licensed the China rights to a phosphate binder, Nephoxil, from Panacor Bioscience Ltd. of Taiwan. Phosphate binders are routinely prescribed for end stage renal disease, the same population served by 3SBios major products, the recombinant anemia drugs EPIAO and TPIAO. More details...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170106&full=1SAN DIEGO--(BUSINESS WIRE)--AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170109&full=1EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. a translational and personalized medicine development company, today announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) in the area of Alzheimers disease and other neurodegenerative conditions. This agreement builds on the original collaboration between the two companies begun in June 2009. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170116&full=1HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced that it has identified a global partner for the possible development of a Clinical Treatment Facility in Panama. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170080&full=1<p> SHENYANG, China, Feb. 8 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170129&full=1LONDON--(BUSINESS WIRE)--APCER Pharma announced that LPC Pharma Group is outsourcing its pharmacovigilance/drug safety operations to APCER. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170142&full=1NEW YORK--(BUSINESS WIRE)--Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170146&full=1<div id"releaseBody"><p>BUENA PARK, CA--(Marketwire - February 08, 2010) - SOHM, Inc. (PINKSHEETS: <a href"http://www.marketwire.com/mw/stock.jsp?TickerSHMN">SHMN</a>), a genericpharmaceutical manufacturer that produces and markets generic drugscovering all major treatment categories, announced today that is has signeda marketing agreement adding 75 branded generic pharmaceutical products...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170155&full=1Gothenburg, Sweden -- Denator AB announced today that the company has signed an exclusive distribution agreement with Basel-based Bucher Biotec AG. Bucher will handle sales and service in Switzerland for Denators heat inactivation technology, Stabilizor T1. </p><p>Based on the companys proprietary heat inactivation technology, Stabilizor T1 stabilizes tissue from the crucial moment of sampling...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170113&full=1WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: Development of an alpha6*-selective Neuronal Nicotinic Receptor (NNR) Imaging...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170074&full=1<p></p><p>LONDON and PALO ALTO, Calif., Feb. 8 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) today announced that the United States Patent and Trademark Office (USPTO) has issued the company a notice of allowance on a patent application directed to methods of treatment using a high-value therapeutic target in the area of oncology. Known as PKN-3, the target is a protein kinase C-related molecule...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170114&full=1TAMPA, Fla.--(BUSINESS WIRE)--Walgreens, the countrys largest drug store chain, will offer EvoraPlusTM, the groundbreaking oral care probiotic mint from Florida-based biotechnology company Oragenics, Inc. (OTCBB: ORNI) (www.oragenics.com) chain-wide beginning March 19, 2010. The introduction of EvoraPlusTM into Walgreens retail locations follows the successful launch of the innovative oral care product...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170120&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for the Soutschek and Manoharan patent (Application No. 10/916,185), which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170160&full=1SAN DIEGO--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a specialty CRO with a pipeline of products based on the NexACT technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMeds option in either cash or shares of unregistered common stock...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170153&full=1<div id"releaseBody"><p>FAIR LAWN, NJ--(Marketwire - February 08, 2010) - Vyteris, Inc. (OTCBB: <a href"http://www.marketwire.com/mw/stock.jsp?TickerVYTR">VYTR</a>), developer of thefirst FDA-approved active transdermal drug delivery system and a leader inactive transdermal drug delivery technology, announced today the privateplacement of $1,060,000 of Senior Subordinated Convertible Promissory...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170131&full=1TARRYTOWN, N.Y.--(BUSINESS WIRE)--Regulatory News: EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm: EPCT) announced today that it has established an at-the-market program through which it may sell, from time to time and at its sole discretion, shares of its common stock having an aggregate offering price of up to $15 million. Maxim Group LLC is acting as sales agent on the program. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170132&full=1ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (Nasdaq: INHX) (the Company), a biopharmaceutical company focused on developing products to treat serious infectious diseases, announced today that it has received notice from The NASDAQ Stock Market ("Nasdaq") stating that, as the bid price of the Companys common stock has closed at or above $1.00 per share for 10 consecutive business days, the Company...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170110&full=1CARLSBAD, Calif.--(BUSINESS WIRE)--Verdezyne, Inc., a privately-held synthetic biology company developing processes for renewable chemicals and fuels, today announced they are developing a new fermentation process for the production of adipic acid. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170147&full=1<div id"releaseBody"><p>MONTREAL, QUEBEC--(Marketwire - February 08, 2010) - ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS<p>Ambrilia Biopharma Inc. (TSX: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSX:AMB">AMB</a>) is providing today its bi-weekly Default Status Report under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("Default Status Report")...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170071&full=1<p></p><p>SEATTLE, Feb. 8 /PRNewswire-FirstCall/ -- On Thursday, February 11, 2010, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) management team will host a conference call to discuss the Company's 2009 fourth quarter and year-end achievements and financial results.</p><p></p><p></p><p></p><p></p><p></p><p></p><p>Cell Therapeutics, Inc...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170092&full=1<p> HARBIN, China, Feb. 8 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheet: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), announced today that it has filed its annual report on Form 10-K for the fiscal year ended October 31, 2009 on time. In addition, the...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170099&full=1TORONTO, Feb. 8, 2010 (GLOBE NEWSWIRE) -- Transition Therapeutics Inc. ("Transition" or the "Company") (Nasdaq:TTHI) (TSX:TTH) will hold a conference call on Wednesday, February 10, 2010 at 4:30 P.M. EST to discuss Second Quarter fiscal 2010 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170122&full=1KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced today that it has named David Soergel, M.D. vice president and head, clinical development. In this role, Dr. Soergel is responsible for shaping Trevenas clinical strategy and the operational execution of its development programs. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170163&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced that John R. Richert, M.D., will be joining the Company as a Senior Fellow in Neurology Research and Development and Nancy D. Richert, M.D., Ph.D., will be joining as a Fellow in Neurology Research and...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170159&full=1MADISON, Wis.--(BUSINESS WIRE)--BioForward, the member-driven organization that represents the states biotechnology industry, today announced the 2010 executive committee members of its board of directors. The BioForward Executive Committee Board Members are:Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170091&full=1LOS ALTOS, Calif., Feb. 8 /PRNewswire/ -- InteKrin Therapeutics Inc announced today that the Company's co-founder and Scientific Advisory Board Chairman, Christos Mantzoros, M.D., DSc., FACP, FACE, has been appointed Professor of Medicine at Harvard Medical School and Professor in Environmental Health at the Harvard School of Public Health.</p><p>Dr. Mantzoros is a member of Harvard's Division...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170085&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170161&full=1Surrey, UK, 8th February 2010 - NextPharma, the leading European provider of product development, contract manufacturing and cold chain and logistics outsourcing services to the pharmaceutical and biotechnology industries, is pleased to announce that it has appointed a new management team at its San Diego facility in California, North America. </p><p>Ronald W. Collins has been appointed as Interim...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170158&full=1Martinsried/Munich, Germany, February 8, 2010 -- SuppreMol GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of autoimmune diseases, today announced that Dr. Robert Phelps has joined the Company as Head of Business Development & Licensing. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170133&full=1WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) released today a letter to Health and Human Services Secretary Kathleen Sebelius regarding the potentially harmful recommendations of the Secretarys Advisory Committee on Genetics, Health and Society (SACGHS) in its Report on Gene Patents and Licensing Practices and Their Impact on Patient Access to Genetic Tests. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170134&full=1BRISBANE, Calif.--(BUSINESS WIRE)--Addressing the importance of job creation, BayBio and Assemblyman Jerry Hill announced legislation to retain and attract California's second largest employing industry during a press conference at an R&D lab in Northern California. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170141&full=1VALLEY FORGE, Pa.--(BUSINESS WIRE)--AmerisourceBergen (NYSE:ABC) announced a unique offering designed to help hospitals and health systems achieve meaningful use readiness for electronic health records (EHR), regardless of the technology they are using. The offering will be provided through Pharmacy Healthcare Solutions (PHS), a professional healthcare consulting business unit of AmerisourceBergen...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170157&full=1Lincolnshire, Illinois -- BioSante Pharmaceuticals, Inc. President and CEO Stephen M. Simes, was interviewed for "Med Tech Sentinel" and featured on its website. </p><p>Program host Bill Dawson interviewed Mr. Simes regarding the development program for LibiGel (testosterone gel), now in Phase III safety and efficacy trials, and on BioSante financial condition and upcoming milestones.</p><p...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170118&full=1RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles, the worlds leading biopharmaceutical services company, has again been named to Training magazines Training Top 125, the publications annual report that ranks companies based on their employer-sponsored training and development programs. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170115&full=1NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, has been invited to present at the Inaugural UCL One Day Finance Conference to be held on February 15th. The event will take place in London, England at the BMA (British Medical Association) House, once home to Charles Dickens. The conference aims to give participants...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170135&full=1NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank recognized for providing financing and advisory services to emerging growth companies worldwide, today announced that their 22nd Annual OC Growth Stock Conference will be held March 15-17, 2010 at The Ritz Carlton, located at 1 Ritz Carlton Drive, Dana Point, California. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170124&full=1MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the companys product development programs at 10:30 a.m. EST on Tuesday, February 9, 2010, at the 12th Annual BIO CEO & Investor Conference in New York City. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170162&full=1NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, will present at the 12th Annual BIO CEO & Investor Conference tomorrow, Tuesday, February 9, 2010 at 3:00 PM EST. Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170121&full=1<p></p><p>ROCKVILLE, Md., Feb. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 12(th) Annual BIO CEO & Investor Conference on February 8(th), 2010 at 1:30 pm local time. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO CEO & Investor...Mon, 08 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169933&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170021&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169952&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169953&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169951&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169802&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170014&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169678&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169981&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169954&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169963&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170011&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169977&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169927&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170026&full=1RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Talecris Biotherapeutics, Inc. (Nasdaq: TLCR) announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169982&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169984&full=1<!-- AddThis Button BEGIN --><script type"text/javascript">var addthis_pub"bdwyer";</script><a href"http://www.addthis.com/bookmark.php?v20" onmouseover"return addthis_open(this, '', '[URL]', '[TITLE]')" onmouseout"addthis_close()" onclick"return addthis_sendto()"><img src"http://s7.addthis.com/static/btn/sm-share-en.gif" width"83" height"16" alt"Bookmark and Share" style"border:0...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170032&full=1<div id"releaseBody"><p>BOSTON, MA--(Marketwire - February 05, 2010) - <table class"releaseLink"><tr><td class"releaseLink"><b>Highlighted Links</b></td></tr><tr><td><p>&nbsp;</p><a href"http://www2.marketwire.com/mw/mmframe?prid584374&attachid1170188">Stonebridge Associates</a></td></tr></table> Allergan, Inc., a leading multi-specialtyhealthcare company, acquired Serica Technologies, Inc...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169970&full=1RANCHO CORDOVA, Calif., Feb. 4 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products for processing and storing adult stem cells, today announced a new enhanced distribution agreement with GE Healthcare, a unit of General Electric Company (NYSE: GE), for its AXP AutoXpress (AXP) System used in the processing of cord blood. Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169978&full=1IPSWICH, Mass., Feb. 4 /PRNewswire/ -- As an important supplier to the Wellcome Trust Sanger Institute, New England Biolabs is pleased to announce that the Sanger Institute will use New England Biolabs as one of its suppliers for next-generation sequencing library construction reagents.Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170013&full=1Melbourne, Feb 5, 2010 (ABN Newswire) - Benitec Limited (ASX:BLT)(PINK:BNIKF) licensee company Tacere Therapeutics, Inc. announced today that Pfizer (NYSE:PFE) has exercised the option, granted in a collaboration and license agreement previously announced in January 2008, to further develop and commercialise Tacere's Hepatitis C Virus (HCV) compounds.Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169956&full=1PHILADELPHIA, Feb. 4 /PRNewswire/ -- TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4) from Genmab A/S (OMX: GEN).Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169969&full=1MISSISSAUGA, ON, Feb. 4 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has issued a notice of redemption...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170001&full=1<p></p><p>ROCKVILLE, Md., Feb. 4 /PRNewswire-FirstCall/ -- EntreMed, Inc. today announced that it completed a registered direct offering of 3,846,154 shares of its common stock, at a purchase price of $0.65 per share, to a single accredited institutional investor. The sale resulted in gross proceeds to the Company of $2.5 million. The terms of the purchase were set forth in a stock purchase agreement...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170031&full=1<div id"releaseBody"><p>NEW WESTMINSTER, BRITISH COLUMBIA--(Marketwire - February 05, 2010) - TSX Venture Exchange today announced that ALDA Pharmaceuticals Corp. (TSX VENTURE: <a href"http://www.marketwire.com/mw/stock.jsp?TickerTSXV:APH">APH</a>) (the "Company" or "ALDA") has been named as one of the TSX Venture 50, a ranking of strong performers listed on TSX Venture Exchange. TSX Venture...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170036&full=1<div id"releaseBody"><p>HERCULES, CA--(Marketwire - February 04, 2010) - Bio-Rad Laboratories, Inc. (NYSE: <a href"http://www.marketwire.com/mw/stock.jsp?TickerBIO">BIO</a>) and(NYSE: <a href"http://www.marketwire.com/mw/stock.jsp?TickerBIO-B">BIO.B</a>), a multinational manufacturer and distributor of life scienceresearch and clinical diagnostics products, today announced that it has...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169972&full=1NOVATO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced 2010 financial guidance. The reconciliation of the non-GAAP measures to the estimated GAAP net income is detailed in the table provided in the press release.Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170020&full=1<p>BEIJING, CHINA, Feb. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) brings attention to a certain previously released news announcements namely January 7 2009, November 19, 2009, Dec 15, 2009 January 12,2010, and January 22, 2010.</p><p>These are significant dates and important events for the company as all of these events are now starting to crystallize and...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170030&full=1Thermo Fisher Scientific Inc., the world leader in serving science, recently announced the availability of the new Thermo Scientific Aspire Protein A, Protein G and IMAC Cobalt Chromatography Tips. Aspire proteomic tips are 1 ml pipette tips embedded with various Thermo Scientific Pierce resins, including immobilized Protein A Plus, Protein G Plus, and HisPur Cobalt resins. These pipette tips utilize...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169980&full=1JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that several of its subsidiaries in the United States reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys, Inc. on behalf of the United States, Texas, Florida, and California under federal and state False Claims Acts. Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169986&full=1OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, announced today that its new cell production facility has passed final building inspection, which will enable development and manufacturing of the company and its partners clinical-grade stem cell products. Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170027&full=1STATESVILLE, N.C., Feb. 5 /PRNewswire-FirstCall/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU), a leader in the design, manufacture, and installation of scientific and technical furniture, today announced plans for the expansion and renovation of its Statesville operations. Construction will soon begin on a 32,000 square foot addition to one of its three manufacturing plants in Statesville, followed...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169996&full=1WALTHAM, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) today reported financial results for its third quarter of fiscal 2010, which ended on December 31, 2009. Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169999&full=1SAN DIEGO--(BUSINESS WIRE)--Accelrys, Inc. (NASDAQ: ACCL) today reported financial results for the quarter ended December 31, 2009. Revenue for the quarter increased 7% to $22.1 million from $20.6 million for the same quarter of the previous year. Revenue for the nine months ended December 31, 2009 increased 2% to $62.2 million from $61.0 million for the same period of the previous year. Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170006&full=1LAKE SUCCESS, N.Y., Feb. 5, 2010 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced results of operations for its fiscal 2010 second quarter and six months ended December 31, 2009.Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169995&full=1DANBURY, Conn.--(BUSINESS WIRE)--Biodel Inc. (Nasdaq: BIOD) today reported financial results for the first fiscal quarter ended December 31, 2009. Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169997&full=1MELBOURNE, Australia--(BUSINESS WIRE)--Biota Holdings Limited (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009. The figures were calculated on an Australian dollar exchange rate of 1.8182 to the UK pound, although the actual payment will...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170028&full=1MISSISSAUGA, ON, Feb. 5 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND), will host a conference call on Wednesday, February 17, 2010 at 8:30 a.m. (ET) to discuss its fiscal 2009 fourth quarter and year end financial results. Cipher invites all interested parties to participate. You can join the call by dialing 647-427-7450 or 1-888-231-8191. Please call in 15 minutes prior to the call to secure a line...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169998&full=1<p> XI'AN, China, Feb. 4 /PRNewswire-Asia-FirstCall/ -- Huifeng Bio- Pharmaceutical Technology, Inc. , a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today announced preliminary 2009 results and provided guidance for 2010.</p><p> Huifeng Bio-Pharmaceutical Technology anticipates revenues between...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170005&full=1SOMERSET, N.J., Feb. 5, 2010 (GLOBE NEWSWIRE) -- inVentiv Health, Inc. (Nasdaq:VTIV) today announced that it will release its Fourth Quarter and Full Year 2009 results and conduct a conference call on Wednesday, February 24 at 8:30 a.m. EST.Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169991&full=1WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI) - Revenue of $498 million, flat with prior year; Organic revenue down 5%Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170041&full=1ALBANY, Ore., Feb. 5 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) today announced it will issue third quarter financial results before the opening of the market on Thursday, February 11, 2010. Following the release of its financial results, Synthetech will host a conference call at 1:30 p.m. PST. Dr. Gregory Hahn, President and CEO, along with Gary Weber, Vice President of...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169994&full=1CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on recent progress in its late-stage development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF), reported consolidated financial results for the year ended December 31, 2009 and provided financial guidance for 2010. Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170022&full=1RESEARCH TRIANGLE PARK, N.C., Feb. 4 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Gwendolyn Powell Painter, M.D., M.P.H., has joined the company as Chief Medical Officer. Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169961&full=1CRANBURY, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that its Board of Directors has elected John F. Crowley as Chairman of the Board in addition to his current role as Chief Executive Officer (CEO), effective immediately. Mr. Crowley will succeed Donald J. Hayden, Jr., who will become the Lead Independent Director of the Board.Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=170024&full=1ALBUQUERQUE, N.M. Bob Cashman, director of new business development atOsoBio, has been appointed to the board of directors at the PDE: A PharmaceuticalTrade Association.</p><p>As the nations oldest active trade association, the PDE serves pharmaceuticalmanufacturers, allied trade industries and pharmacy schools. It also provides a forumfor interaction, communication and education among...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169989&full=1WASHINGTON--(BUSINESS WIRE)--Additional Congressional action is needed to follow through on the Obama administrations recently announced initiative to rapidly build an integrated value chain for the bioeconomy, create jobs and kick start economic growth. The Biotechnology Industry Organization (BIO) today released proposed policy options that provide needed incentives to support U.S. job growth incentivizing...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169962&full=1VILLA GUARDIA, Italy, Feb. 5 /PRNewswire-FirstCall/ -- Gentium S.p.A. (Nasdaq: GENT) today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study," has been awarded the Van Bekkum Award for the best abstract submitted to the physician's program...Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169958&full=1SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the 12th Annual BIO CEO and Investor Conference.Fri, 05 Feb 2010 12:00:00 AM GMThttp://www.biospace.com/news_story.aspx?StoryID=169964&full=1SOUTH SAN FRANCISCO, Calif., Feb. 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 12th Annual BIO CEO & Investor Conference in New York City on Monday, February 8th at 10:00 a.m. EST.Fri, 05 Feb 2010 12:00:00 AM GMT